The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
October 27, 2025
View Complete Issue         Table of Contents 2019 
Intravesical Gemcitabine (Inlexzo) for Bladder Cancer (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Intravesical Gemcitabine (Inlexzo) for Bladder Cancer (online only)
October 27, 2025 (Issue: 1740)
The FDA has approved Inlexzo, a gemcitabine intravesical system, for treatment of Bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ, with or without papillary tumors. The Inlexzo system...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Intravesical Gemcitabine (Inlexzo) for Bladder Cancer (online only)
Article code: 1740c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.